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Introduction. Preclinical and clinical evidences for a role of oral probiotics in the management of allergic diseases are emerging.
Aim. We aimed at testing the immunomodulatory eﬀects of intranasal versus intragastric administration of Lactobacillus paracasei
NCC2461 in a mouse model of allergic airway inflammation and the specificity of diﬀerent probiotics by comparing L.
paracasei NCC2461 to Lactobacillus plantarum NCC1107. Methods. L. paracasei NCC2461 or L. plantarum NCC1107 strains were
administered either intragastrically (NCC2461) or intranasally (NCC2461 or NCC1107) to OVA-sensitized mice challenged with
OVA aerosols. Inflammatory cell recruitment into BALF, eotaxin and IL-5 production in the lungs were measured. Results.
Intranasal L. paracaseiNCC2461 eﬃciently protected sensitized mice upon exposure to OVA aerosols in a dose-dependent manner
as compared to control mice. Inflammatory cell number, eotaxin and IL-5 were significantly reduced in BALF. Intranasal supple-
mentation of L. paracasei NCC2461 was more potent than intragastric application in limiting the allergic response and possibly
linked to an increase in T regulatory cells in the lungs. Finally, intranasal L. plantarum NCC1107 reduced total and eosinophilic
lung inflammation, but increased neutrophilia and macrophages infiltration. Conclusion. A concerted selection of intervention
schedule, doses, and administration routes (intranasal versus intragastric) may markedly contribute to modulate airway inflam-
mation in a probiotic strain-specific manner.
1. Introduction
Respiratory allergy results from inappropriate adaptive
immune responses to ubiquitous, otherwise most often
innocuous environmental proteins. The immunological hall-
marks of respiratory allergy are mainly characterized by
the aberrant production of Th2 cytokines (IL-4, IL-5, IL-
13) and the induction of IgE and chemokines involved in
the recruitment of lymphocytes and eosinophils into the
lungs. While proteins targeted by airway allergic responses
represent a tiny fraction of airborne proteins humans are
exposed to, allergenicity is a quite common phenomenon.
Genetic predisposition has a key role in allergy expression,
but substantial evidences have emerged emphasizing that the
microbial environment is a major player in maintaining a
Th1/Th2 homeostasis. This concept relies on the “hygiene
hypothesis” stating that avoidance of microbial exposure
during early infancy increases the risk of developing allergic
diseases [1–3].
Probiotics are defined as live microorganisms which
confer a health benefit on the host when administered in ade-
quate amounts [4]. Originally thought to be due to improve-
ments in the intestinal microbial balance, probiotics bene-
ficial eﬀects may also stem from their capacity to modulate
the host immune response [5, 6]. Recent clinical trials, epi-
demiological studies, and animal experiments have suggested
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that probiotics may contribute to suppress the development
of allergic responses. In humans, most successes have been
obtained in primary prevention of atopic eczema, but a
limited number of studies also provided evidence for a
beneficial eﬀect of diﬀerent probiotics in the management of
other allergic diseases such as allergic rhinitis [5]. A few stud-
ies conducted in children and adults with allergic rhinitis
suggested a beneficial eﬀect of specific probiotic strains
(Lactobacillus casei, Bifidobacterium longum, or Lactobacillus
paracasei) [7–9]. Several reports have also shown that pro-
biotic supplementation was eﬀective at preventing asthma
symptoms when administered very early in life [10–12]. To
our knowledge, only few studies showed that oral treatment
with a Lactobacillus reuteri strain inhibited the allergic airway
response in adult mice [13]. These studies derived from the
observation that endotoxin and/or bacterial exposure early
in life, or during pregnancy, protects the oﬀspring against
allergen-induced airway disease [14, 15]. Probiotics may
modulate allergy through immune deviation toward a Th1
immune response or induction of regulatory T cells [16].
These modes of action may overlap or diﬀer depending on
the models used, the intrinsic properties of the probiotics
utilized and their TLR ligand expression.
Lactobacillus paracaseiNCC2461 is a probiotic strain that
was selected on the basis of its safety, its industrial properties
(yield, stability), and its in vitro immune modulation profile.
This strain has been shown to produce antimicrobial meta-
bolites and to increase Th1 cell-dependent immune system
activation as well as regulatory T cells development [5, 6, 17–
19].
We demonstrate in this study that the schedule (prior to,
during, or after OVA sensitization or during OVA aerosol
challenges), the administration routes (intranasal versus
intragastric) and the characteristics of the strain admin-
istered (L. paracasei NCC2461 versus L. plantarum rather
than Lactobacillus NCC1107, used here as a negative control
according to previous in vitro screening and in vivo testing
[20] were key parameters of the modulation of murine
airway inflammation by probiotics.
2. Material and Methods
2.1. Experimental Airway Inflammation. Four-week-old
female BALB/c mice (H-2d) were obtained from Harlan (AD
Horst, The Netherlands) and used at the age of 6–8 weeks.
They were maintained under standard housing conditions
on ovalbumin- (OVA-) free diet and water ad libitum. Mice
were sensitized twice at day 0 and 14 by intraperitoneal
(i.p.) injections of 10 μg of OVA (Fluka, Buchs, Switzerland)
adsorbed on 1mg Alum (Sigma Chemicals, St-Louis, MO,
USA) [21]. On days 26, 28, and 30, animals were exposed
to a single aerosol of OVA in PBS (0.25%). Aerosolization
generated by a nebulizer (De Vilbiss, Sunrise medical GmBH,
Germany) was performedwith amaximumof 12mice placed
in a 30 × 30 × 12 cm plexiglas chamber and exposed for
20min. Animals were sacrificed on day 33.
2.2. Probiotics Administration. The strains L. paracasei
NCC2461 (CNCM I-2116; ST11; Nestle´, Switzerland) and
L. plantarum NCC1107 are part of the Nestle´ Collection
and were provided by Nestle´. Probiotic bacteria at a dose
of 109 CFU (unless other dose specified) were applied intra-
gastrically (i.g.) or intranasally (i.n.), either 12 times during
sensitization phase (Figure 1(a)) or 4 times every other day,
i.e. the days without OVA aerosols (days 25, 27, 29, 31)
(Figure 1(b)). Intragastric administration of probiotics in
PBS was done using a stainless steel feeding tube in a volume
of 100 μL. Intranasal administration of 20 μL probiotics in
PBS or PBS only was performed under light anesthesia with
halothane (Halocarbon B. P., Arovet A. G., Zollikon, Switzer-
land). Material was spontaneously inhaled by the animal.
2.3. Histology. Whole lungs were fixed by inflation and sub-
mersion in 10% buﬀered formalin, embedded in paraﬃn,
and then sectioned. Histopathologic study was made using
Hematoxylin and Eosin (H&E)—and Periodic Acid Schiﬀ
(PAS)—stained lung sections. Representative pictures of
H&E staining were taken. The percentage of PAS staining
positive cells in small- and medium-size airways were
counted out of all the available epithelial cells present on each
section.
2.4. BALF Collection and Cytospin Preparation. At the time
of sacrifice, animals were anesthetized intraperitoneally (i.p.)
with 3mg thiopental sodium (Trapanal, Altana pharma
GmbH, Konstanz, Germany), trachea was cannulated, and
bronchoalveolar lavage (BAL) was performed by injecting
3mL PBS (6 × 500 μL) into the lungs. BAL fluid (BALF) was
immediately stored on ice. Approximately, 105 cells in 100 μL
were centrifuged on glass plates (Cytospin, Shandon scien-
tific, Cheshire, UK) and then stained with DiﬀQuik accord-
ing to manufacturer’s recommendations (Baxter Dade,
Dudingen, Switzerland). A diﬀerential count of 200 cells was
performed using standard morphological criteria.
2.5. IgE Determination by ELISA in Sera. Serum IgE levels
were determined by ELISA as described [22, 23]. Briefly,
after blocking with 1% BSA, 1 : 20 dilutions of mouse serum
(50 μL) were incubated in 96-well Nunc Maxisorp immuno-
plates (Life Technologies, Basel, Switzerland) previously
coated with 5 μg/mL OVA. After three washes in PBS-Tween
0.02%, plates were incubated with 2 μg/mL biotinylated rat
anti-mouse IgE mAb (PharMingen, BD-Biosciences, San
Diego, CA, USA) for two hours and revealed with alkaline
phosphatase. Purified mouse IgE (PharMingen) was used as
a standard. Results were expressed in ng/mL.
2.6. Quantification of Cytokines and Chemokine by ELISA.
Lungs were harvested, snap-frozen in dry ice, and kept
at −80◦C until use. Frozen lungs were homogenized in a
Dounce tissue grinder with 1mL PBS containing protease
inhibitors (Complete, Roche Diagnostics GmbH, Man-
nheim, Germany) and centrifuged for 4min at 1640× g.
Cytokines and chemokines were measured in supernatants
(50 μL) by ELISA according to the manufacturer (PharMin-
gen/BD Biosciences, San Diego, USA, for IL-5 or R&D
Systems, Minneapolis, USA, for eotaxin-1).
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Figure 1: Protocols of probiotic strains administration and subsequent eﬀect of intragastric L. paracasei NCC2461 on total cell number in
BALF of OVA-challenged mice. Mice were sensitized intraperitoneally (i.p.) twice with OVA and subsequently challenged with OVA aerosol
3 times. Mice received NCC2461 intragastrically (i.g.) 12 times before, after, and in between the 2 i.p. sensitizations (a) or 4 times before,
after and in between each OVA challenge (b). Total cell count in the BALF (n = 10) mice per group. In this representative experiment, data
are expressed as mean ± SD; ∗P < 0.05 (c).
2.7. Lungs Cells Isolation and T Regulatory Cells Staining.
Lungs were minced in NaCl 0.9% and incubated 20minutes
at 37◦C in the presence of 0.2 μg/mL Liberase (Roche
Diagnostic GmbH, Mannhein, Germany), 0.1 μg/mL DNase
(Sigma Chemicals, St-Louis, MO, USA), and 5mMCaCl2
(Sigma Chemicals, St-Louis, MO, USA) at 37◦C. They were
then homogenized on a 40 μmcell strainer (BD Falcon, Basel,
USA), rinsed with Dulbecco’s modified Eagle’s medium
supplemented with 10% FCS and centrifuged. Red blood
cells were lysed in lysis buﬀer (0.15M NH4CL, 0.01M
KHCO3), washed, and resuspended in FACS buﬀer (PBS,
1%BSA, 0.01%NaN3). Cells were finally incubated with the
following antibodies: anti-CD4 PerCP (1/200, BDPharmin-
gen), anti-CD25PE (1/300, BD Pharmingen), staining kit
FJK-16s (eBioscience, San Diego, Ca, USA), for 20min on
ice. Foxp3 intracellular staining was performed using anti-
mouse/rat Foxp3 staining set (FJK-16s, eBioscience, San
Diego, CA, USA) according to manufacturer’s protocol. Flow
cytometry acquisitions were performed on a FACScalibur
(BD Biosciences) and analyzed using FlowJo software (Tree
Star Inc., Ashland, OR, USA).
3. Results
3.1. L. paracasei NCC2461 Reduces Inflammatory Cell Recruit-
ment into BALF when Administered by the Intragastric Route
during Allergen Challenges. To investigate the in vivo immu-
nomodulatory properties of L. paracasei NCC2461, several
protocols were used to evaluate the protective eﬀect of this
strain NCC2461 during the diﬀerent phases of the OVA
allergic airway inflammation model. Bacteria were admin-
istered to mice during the sensitization phase (Figure 1(a))
or at the time of aerosol exposure (Figure 1(b)). The intra-
gastric supplementation of L. paracasei NCC2461 during
the aerosol exposures significantly reduced the total cell
number in the BALF (Figure 1(c)). An intragastric dose
of 107 CFU L. paracasei NCC2461 tended to downregulate
inflammatory cell recruitment into the BALF whereas a
higher i.g. dose of 1 × 109 CFU L. paracasei NCC2461 sig-
nificantly reduced cell recruitment as compared to PBS con-
trol, from 1.22 × 106± 6.11 × 105 (mean ± SD) to 6.75 ×
105±2.15×105 total cell number, that is a 45% decrease (P <
0.05) (Figure 1(c)). This protective eﬀect was not significant
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Figure 2: Eﬀect of intragastric versus intranasal L. paracasei NCC2461 administration on lung airway inflammation. L. paracasei NCC2461
(1 × 109 CFU) or PBS were either administered intragastrically (i.g.) or intranasally (i.n.) in OVA-challenged mice. Total cell counts (a)
and diﬀerential cell counts (b) in the BALF. Eotaxin (c) and IL-5 levels (d) in lung homogenate were quantified by ELISA. Histograms are
mean ± SD obtained from one representative experiment, n = 10 mice per group; ∗P < 0.05, ∗∗P < 0.005, ∗∗∗P < 0.0005.
when L. paracaseiNCC2461 was administered i.g. during the
sensitization phase with OVA (data not shown), suggesting
a better protective action of this strain when administered
in already sensitized animals, during the OVA aerosol
challenges. Specific IgE levels in plasma were not aﬀected by
the administration of L. paracaseiNCC2461 in the two exper-
imental settings (data not shown). Globally, these results
indicated that L. paracasei NCC2461, administered intra-
gastrically at a dose of 1 × 109 CFU, significantly impaired
inflammatory cell recruitment into BALF when adminis-
trated to mice during the OVA aerosol exposure phase.
3.2. Intranasal L. paracasei NCC2461 Administration is More
Eﬃcient Than Intragastric Administration in Reducing IL-5
and Eotaxin Production in Lungs. We next tested whether
the administration of L. paracasei NCC2461 (at a dose of
1 × 109 CFU) via the nasal versus gastric route during OVA
aerosol exposure would be able to reduce cell recruitment
into BALF (Figure 1(b)). In agreement with the results
obtained after intragastric administration of L. paracasei
NCC2461 (Figures 1(c) and 2(a)), total cell count in BALF
was decreased in mice given L. paracasei NCC2461 intrana-
sally (i.n.) (Figure 2(a)). Diﬀerential cell count in BALF was
analyzed and a significant 2.1-fold drop in eosinophil num-
bers was observed in mice treated by intragastric L. paracasei
NCC2461 gavage (6.42 × 105 ± 5.23 × 105 versus 2.93 ×
105 ± 2.92 × 105) (Figure 2(b)). Macrophages, neutrophils
and lymphocytes numbers were not significantly altered
under these conditions. Interestingly, intranasal adminis-
tration of L. paracasei NCC2461 was able to dramatically
decrease eosinophilic recruitment into the BALF by 37.8-fold
as compared to PBS-treated group (1.26 × 104 ± 1.16 × 104
versus 4.76 × 105 ± 3.81 × 105, P < 0.0005). Lymphocytes
were also significantly decreased (5.4-fold, P < 0.005) in
L. paracasei NCC2461 intranasally treated mice compared
to PBS-treated mice. OVA-sensitized mice given L. paracasei
NCC2461 intranasally showed a significant drop in IL-5 and
eotaxin (Figures 2(c) and 2(d)) production in lung homo-
genates. During such a short observation period, no eﬀect
of i.n. administration of the strain was observed on specific
IgE quantified in serum (data not shown). Altogether these
results suggested that the intranasal route was more eﬃcient
than the intragastric administration in downregulating key
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Figure 3: Eﬀect of intranasal L. paracasei NCC2461 and L. plantarum NCC1107 on lung airway inflammation. L. paracasei NCC2461
(1 × 109 CFU), L. plantarum NCC1107 (1 × 109 CFU), or PBS were administered intranasally (i.n.) in OVA-challenged mice. Total (a) and
diﬀerential (b) cell counts were performed in the BALF. Eotaxin (c) and IL-5 levels (d) in lung homogenate were quantified by ELISA. Lung
sections were PAS stained (results are expressed as % of PAS positive cells (e)) and H&E stained (f), reflecting the severity and localization of
inflammation (magnification ×10). In this representative experiment, histograms are mean ± SD from 10 animals; ∗P < 0.05, ∗∗P < 0.005,
∗∗∗P < 0.0005.
inflammatory mediators for eosinophil recruitment and
survival into lung airways, that is eotaxin and IL-5, although
final total cell recruitment into BALF was similar.
3.3. L. paracasei NCC2461 Is More Eﬃcient Than L. plan-
tarum NCC1107 to Reduce Airways Inflammation. We next
aimed at testing the specificity of L. paracasei NCC2461 in
reducing airways inflammation by comparing L. paracasei
NCC2461 to L. plantarum NCC1107 administered at the
same dose of 1 × 109 CFU. To this end we selected the
intranasal route of application as it induced more prominent
immune modulation. As previously observed with L.
paracasei NCC2461, total cell recruitment in the BALF
was also significantly reduced when mice were treated
with L. plantarum NCC1107 during OVA aerosol exposure
(P < 0.05) as compared to PBS (9.81 × 105 ± 6.36 × 105
with NCC2461 treatment, 1.08 × 106 ± 3.84 × 105 with
NCC1107 treatment and 1.88×106±9.27×105 with the PBS
treatment, Figure 3(a)). Both Lactobacillus strains induced
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a decrease in eosinophils and lymphocytes recruitment into
the lungs (Figure 3(b)) that was accompanied and supported
by a reduced production of IL-5 (Figure 3(c)) and eotaxin
(Figure 3(d)). However, only L. plantarum NCC1107
induced a significant neutrophil influx (4.8-fold, P < 0.05)
into BALF, not observed after L. paracasei NCC2461 admin-
istration (Figure 3(b)). These diﬀerences were also illustrated
histologically. A significant reduction of PAS-staining
positive cells was observed in the lungs of NCC2461-treated
mice while no significant changes were observed in
NCC1107-treated mice (P = 0.114; Figure 3(e)). Based on
H&E staining, the lungs of NCC2461-treated animals were
presenting less perivascular inflammation than the PBS
control group (Figure 3(f)). It is interesting to note that,
while the total BAL cell count and absolute BAL eosinophilia
were reduced in the NCC1107-treated mice BAL, a profound
tissue lung inflammation, not only restricted to the peri-
vascular zone, was observed in this group (Figure 3(f)).
Similarly to what was observed after L. paracasei NCC2461
i.n. administration, levels of specific IgE in plasma were
similar in the group of mice administered i.n. with L. plan-
tarum NCC1107 and in the control group (data not shown).
Taken together these results suggested that L. paracasei
NCC2461 and L. plantarum NCC1107 have diﬀerent modu-
latory competences on allergic lung airway inflammation,
and that L. plantarum NCC1107 may, in respect to neutro-
phil recruitment, even lead to enhanced airways inflam-
mation.
3.4. L. paracasei NCC2461 Increases Regulatory T Cells in the
Lungs. To better understand the beneficial role of intranasal
administration of L. paracasei NCC2461 in this respiratory
allergy mouse model, we investigated the presence of regula-
tory T cells in lungs of mice treated with NCC2461. Although
the diﬀerence was small, the percentage of CD4+CD25+
cells expressing Foxp3 was significantly higher in NCC2461
treated mice than in PBS controls (Figure 4). This decrease
may be associated with the observed downregulation of
inflammatory markers and cell infiltrates in the lungs and
BALF of probiotic-treated mice.
4. Discussion
Probiotic supplementation for prevention or reduction of
allergic symptoms is well documented, but conflicting results
have been reported so far. Here, we demonstrate that the
probiotics administration schedule, dose, strain, and routes
were key parameters for a reliable downregulation of airways
allergic inflammation. The decrease in pulmonary cell
infiltrates observed in our model was marked and consistent
across experiments, and the downregulation of inflamma-
tory markers (IL-5, eotaxin) quite substantial. These results
can be compared to the eﬀect obtained with steroids in
human asthma [24]. In humans, however, trials involving
probiotics have often led to mild and variable eﬀects on
allergic inflammation, which may reflect a greater impact of
confounding factors as compared to a “controlled” mouse
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Figure 4: Percentage of FoxP3 positive cells in the CD4+CD25+ T
cell population in the lung of mice treated intranasally with PBS or
with NCC2461. One representative experiment out of two indepen-
dent experiments. ∗∗P < 0.005.
model. It is however important to keep in mind that pro-
biotics in humans were primarily investigated to delay onset
and to decrease incidence and prevalence of allergy symp-
toms, or ultimately to alleviate them, and to improve
quality of life of patients. In this study, probiotics were
able, in a therapeutic manner, to significantly modulate
allergic inflammatory markers such as lung eosinophilia and
lymphocyte recruitment as well as lung eotaxin and IL-5 pro-
duction. Of note, diﬀerent routes of probiotic administration
generated diﬀerent immune eﬀects; indeed the application
of probiotics directly to the respiratory mucosa was more
eﬀective at decreasing key allergic features (IL-5, eotaxin)
than the intragastric route. This could result from the fact
that the nasal cavity corresponds to a less complex ecosystem
than the gastro-intestinal tract. Moreover, the capacity to
modulate inflammation appeared to diﬀer between the two
strains studied.
Several studies have shown that probiotic supplemen-
tation was eﬀective in preventing allergic airway symptoms
when administered early in life [11, 12, 17, 18]. Bacterial
exposure early in life, or during pregnancy, has been shown
to protect the oﬀspring against allergen-induced airway dis-
ease [14]. Another study described the therapeutic potential
of oral treatment with a strain of Lactobacillus reuteri on
allergic airway response in mice [13]. Interestingly, the oral
administration of another strain (Lactobacillus salivarius) in
the same animal model did not show any beneficial eﬀect,
underlining the specificity of the strain for a given health
benefit. In our study as well, the two tested Lactobacillus
strains had specific properties. While L. plantarumNCC1107
was eﬃcient at reducing eosinophil influx into the BALF,
it also increased significantly neutrophilia, a phenomenon
never observed with L. paracasei NCC2461. Interestingly, L.
plantarum NCC1107 had no eﬀect in another allergy model
(intestinal food allergy model) [20].
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Probiotics may modulate allergy through immune devi-
ation toward a Th1 immune response or through the
induction of regulatory T cells [25]. L. paracasei NCC2461
has been widely studied and has been precisely shown to
induce the production of immunomodulatory as well as Th1
cytokines in vivo and in vitro [18]. Here, we demonstrated
that L. paracasei NCC2461 was less eﬀective at prevent-
ing the induction of specific markers of airways allergic
inflammation (IL-5, eotaxin) when delivered intragastrically,
as opposed to intranasally, during the challenge phase.
Nonetheless, the final total inflammatory cell numbers in
BALF were similar, suggesting potentially two modulation
pathways diﬀering when generated in the respiratory or in
the gastrointestinal tract. We also demonstrated that the
eosinophilic lung infiltrate was more eﬃciently reduced
when probiotics were administered intranasally as compared
to intragastrically. This suggested a direct crosstalk between
the nasal and the lung mucosae to eﬃciently counteract
the Th2 response as previously demonstrated [21]. Eotaxin
was not significantly decreased after intragastric L. paracasei
NCC2461 but eosinophilia was nonetheless reduced. This
may result from a potential inhibitory action of probiotics
on lung eosinophilic recruitment via a systemic eﬀect or
by decreasing other chemokines. Finally, in agreement with
other studies in spleen [26], or in peribronchial lymph nodes
[11], we showed that the CD4+CD25+Foxp3+ T cell popu-
lation was increased in the lungs of L. paracasei NCC2461-
treated mice as compared to the lungs of control animals.
As also demonstrated in a model of tolerance to OVA via
the nasal mucosa, this enhancement of the T regulatory cell
subpopulation may contribute to the mechanisms responsi-
ble for the anti-inflammatory eﬀect of L. paracasei NCC2461
[27].
Altogether, these results confirm the potential interest of
probiotics in allergy management and the previously known
concept that the health benefits delivered by probiotics are
highly strain specific. Additionally, their eﬃcacy at a defined
site and in a precise model cannot be generalized to all sites,
strains or models. As such, while murine models can help
selecting probiotics with anti-inflammatory or anti-allergy
potential, clinical trials in allergic patients will need to be
performed to definitively establish their eﬃcacy and to better
understand their specific eﬀects in the human host. Impor-
tantly, the potential benefit of L. paracaseiNCC2461 was sup-
ported in humans by two recent pilot clinical trials in which
L. paracasei NCC2461 consumption was able to decrease
inflammatory cell infiltrates in the nasal mucosa of adults
suﬀering from grass pollen-induced allergic rhinitis [8].
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